Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase JAK1 (Homo sapiens (Human)) | BDBM398506![]() ((2R)-1,1,1-Trifluoro-3-({cis-4-[(1-methyl-4-{[1-(p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 1.49 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 (Homo sapiens (Human)) | BDBM398504![]() ((2R)-1,1,1-Trifluoro-3-[(cis-1-methyl-4-{[1-methyl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 1.91 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 (Homo sapiens (Human)) | BDBM398501![]() ((2R)-1,1,1-Trifluoro-3-({cis-4-[(4-{[1-(3-methoxyp...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 3.25 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 (Homo sapiens (Human)) | BDBM398502![]() ((2R)-1,1,1-Trifluoro-3-{[cis-4-({4-[(5-methoxy-1-m...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 5.25 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 (Homo sapiens (Human)) | BDBM398505![]() ((2R)-3-{[cis-4-({4-[(1,5-Dimethyl-1H-pyrazol-3-yl)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 5.35 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 (Homo sapiens (Human)) | BDBM398503![]() ((2R)-3-{[(cis-4-({4-[(Ethyl-5-methyl-1H-pyrazol-3-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 5.43 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK2 (Homo sapiens (Human)) | BDBM398506![]() ((2R)-1,1,1-Trifluoro-3-({cis-4-[(1-methyl-4-{[1-(p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 220 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK2 (Homo sapiens (Human)) | BDBM398504![]() ((2R)-1,1,1-Trifluoro-3-[(cis-1-methyl-4-{[1-methyl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 239 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK3 (Homo sapiens (Human)) | BDBM398506![]() ((2R)-1,1,1-Trifluoro-3-({cis-4-[(1-methyl-4-{[1-(p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 660 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK2 (Homo sapiens (Human)) | BDBM398505![]() ((2R)-3-{[cis-4-({4-[(1,5-Dimethyl-1H-pyrazol-3-yl)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 767 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK2 (Homo sapiens (Human)) | BDBM398502![]() ((2R)-1,1,1-Trifluoro-3-{[cis-4-({4-[(5-methoxy-1-m...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 768 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK2 (Homo sapiens (Human)) | BDBM398503![]() ((2R)-3-{[(cis-4-({4-[(Ethyl-5-methyl-1H-pyrazol-3-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 901 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK3 (Homo sapiens (Human)) | BDBM398504![]() ((2R)-1,1,1-Trifluoro-3-[(cis-1-methyl-4-{[1-methyl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 1.17E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK2 (Homo sapiens (Human)) | BDBM398501![]() ((2R)-1,1,1-Trifluoro-3-({cis-4-[(4-{[1-(3-methoxyp...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK3 (Homo sapiens (Human)) | BDBM398505![]() ((2R)-3-{[cis-4-({4-[(1,5-Dimethyl-1H-pyrazol-3-yl)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 2.14E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK3 (Homo sapiens (Human)) | BDBM398502![]() ((2R)-1,1,1-Trifluoro-3-{[cis-4-({4-[(5-methoxy-1-m...) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 2.54E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK3 (Homo sapiens (Human)) | BDBM398501![]() ((2R)-1,1,1-Trifluoro-3-({cis-4-[(4-{[1-(3-methoxyp...) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 3.72E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK3 (Homo sapiens (Human)) | BDBM398503![]() ((2R)-3-{[(cis-4-({4-[(Ethyl-5-methyl-1H-pyrazol-3-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | Article US Patent | n/a | n/a | 6.16E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Eli Lilly and Company US Patent | Assay Description The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th... | US Patent US10323019 (2019) Article DOI: null BindingDB Entry DOI: 10.7270/Q2TF00QZ | |||||||||||
More data for this Ligand-Target Pair |